2015 American Transplant Congress
Long-Term Results After Heart Transplantation – A Randomized Trial Comparing Tacrolimus Versus Cyclosporine A in Combination With Mycophenolate Mofetil After a Mean Duration of 15 Years
Purpose. Development of cardiac allograft vasculopathy (CAV), renal dysfunction and malignancies are the main risks due to long-term immunosuppressive therapy after heart transplantation (HTx). We…2015 American Transplant Congress
Tracking T Cell Fate After Antithymocyte Globulin (ATG) Immunotherapy in Infant Heart Transplant (HTx) Patients
Polyclonal T cell depletion with ATG is a common induction therapy in adult and pediatric transplantation. In adults, T cell recovery post-ATG involves homeostatic proliferation…2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
The Correlation Between Donor Specific Antibodies and Heart Transplant Rejection
The presence of donor specific HLA antibodies (DSA) has been shown to be detrimental to heart transplant (HTx) survival. Virtual crossmatching (VXM) offers a rapid…2015 American Transplant Congress
Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease After Treatment in Organ Transplant Recipients
1CareDx, Inc, Brisbane, CA; 2Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a potential biomarker of acute cellular rejection (ACR) in organ transplant recipients. dd-cfDNA levels in longitudinal plasma samples from…2015 American Transplant Congress
C1q Reactivity and IgG Subtypes After HLA Antibody Removal Therapy With Carfilzomib in Thoracic Transplant Recipients
Univ of Pittsburgh, Pittsburgh.
Conventional therapies for antibody removal consisting of plasma exchange with IVIG and Rituximab are partially effective in desensitization protocols and for treatment of antibody mediated…2015 American Transplant Congress
Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: The development of donor-specific antibodies (DSA) after heart transplant has been correlated to the subsequent development of graft rejection. The development of DSA are…2015 American Transplant Congress
Elevated ST2 Levels Are Associated With Increased Risk of Antibody Mediated Rejection in Heart Transplant Recipients
Objective: Serum ST2, a member of the interleukin (IL) 1 receptor family, is a novel biomarker that reflects cardiac remodeling and fibrosis and is associated…2015 American Transplant Congress
Longitudinal Multi-Omic Profiling of Genes and Pathways Underlying Cardiac Allograft Rejection
Our ability to treat cardiac allograft rejection in both acute and chronic states is typically limited by poor existing biomarkers to predict the occurrence of…2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…
American Transplant Congress abstracts